BioHarvest Sciences vs Lexicon Pharmaceuticals
BHST and LXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BHST and LXRX compare
BioHarvest Sciences grew revenue faster over the last twelve months (37.0% versus −45.6% for Lexicon Pharmaceuticals).
BioHarvest Sciences keeps more of each dollar of sales as profit, with a net margin of −32.3% compared with −162% at Lexicon Pharmaceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BHST | LXRX |
|---|---|---|
| Size and price | ||
| Market cap | – | $796M |
| Share price | $1.50 | $1.79 |
| Change, 1 year | −80.9% | 16.2% |
| Change, 5 years | −86.1% | −63.9% |
| Beta (5Y) | 0.87 | 1.76 |
| Employees | – | 81 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 20.7× |
| P/B | – | 4.9× |
| Fair value | – | $0.871 |
| Margin of safety | – | −106% |
| Growth | ||
| Revenue growth (TTM) | 37.0% (better) | −45.6% |
| Revenue growth, 5Y average | – | 15.7% |
| Profitability | ||
| Gross margin | 59.3% | 98.9% (better) |
| Operating margin | −16.2% (better) | −147% |
| Net margin | −32.3% (better) | −162% |
| FCF margin | −27.8% | – |
| Return on equity | −83.2% | −43.9% (better) |
| Return on invested capital | −163% | −140% (better) |
| Financial health | ||
| Debt / equity | 0.01 (better) | 0.32 |
| Current ratio | 3.97 | 10.63 (better) |
| Altman Z-score | – | −5.60 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −8.9% |
| Shareholder yield | – | −8.9% |
| Ownership | ||
| Held by institutions | 7.4% | 81.9% |
| Held by insiders | 0.00% | – |
| Insider net buying, 12 months | – | $2.8M |
| Short interest, % of float | 0.33% | – |
Go deeper
- BHST stock overview
- BHST income statement
- BHST valuation and score
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.